Elmer Maurits
Guest researcher
- Name
- Dr. E. Maurits
- Telephone
- 071 5272727
- e.maurits@lic.leidenuniv.nl
- ORCID iD
- 0000-0001-9631-9152
Guest researcher
- Faculty of Science
- LIC
- Chemistry for Human Health
- Bio-organic Synthesis
- Miyamoto Y., Hurysz B.M., Fajtova P., Eckmann P., Serafim M.S.M., Kronenberger T., Al-Hindy M., Dekker P.M., Maurits E., Overkleeft H.S, Bergdahl B.M., Almaliti J., Gerwick W.H., O'Donoghue A.J. & Eckmann L. (2025), Inhibitors of the 20S proteasome β5 subunit as potent and selective agents against Trichomonas vaginalis, Antimicrobial Agents and Chemotherapy 69(12): e00893-25.
- Su Q., Louwerse G.A.M., Lammers R.F., Maurits E., Janssen M., Boot R.G., Borlandelli V.B., Offen W.A., Linzel D., Schroder S.P., Davies G.J., Overkleeft H.S., Artola M. & Aerts J.M.F.G. (2024), Selective labelling of GBA2 in cells with fluorescent β-d-arabinofuranosyl cyclitol aziridines, Chemical Science 15(37): 15212-15220.
- Zhou X., Besse A., Peter J., Steinhardt M.J., Vogt C., Nerreter S., Teufel E., Stanojkovska E., Xiao X., Hornburger H., Haertle L., Lopez M.M., Munawar U., Riedel A., Han S., Maurits E., Overkleeft H.S., Florea B.I., Einsele H., Kortüm K.M., Driessen C., Besse L. & Rasche L. (2023), High-dose carfilzomib achieves superior anti-tumor activity over lowdose and recaptures response in relapsed/refractory multiple myeloma resistant to low-dose carfilzomib by co-inhibiting the β2 and β1 subunits of the proteasome complex, Haematologica 108(6): 1628-1639.
- Besse A., Kraus M., Mendez-Lopez M., Maurits E., Overkleeft H.S., Driessen C. & Besse L. (2022), Immunoproteasome activity in chronic lymphocytic leukemia as a target of the immunoproteasome-selective inhibitors, Cells 11(5): 838.
- Besse L., Besse A., Kraus M., Maurits E., Overkleeft H.S., Bornhauser B., Bourquin J.P. & Driessen C. (2021), High immunoproteasome activity and sXBP1 in pediatric precursor B-ALL predicts sensitivity towards proteasome inhibitors, Cells 10(11): 2853.
- Geus M.A.R. de, Maurits E., Sarris A.J.C., Hansen T., Kloet M.S., Kamphorst K., Hoeve W. ten, Robillard M.S., Pannwitz A., Bonnet S.A., Codée J.D.C., Filippov D.V., Overkleeft H.S. & Kasteren S.I. van (2020), Fluorogenic Bifunctional Trans-cyclooctenes as Efficient Tools for Investigating Click-to-Release Kinetics, Chemistry: a European Journal 26(44): 9900-9904.
- Maurits E., Graaff M.J. van de, Maiorana S., Wander D.P.A., Dekker P.M., Zanden S.Y. van der, Florea B.I., Neefjes J.J.C., Overkleeft H.S. & Kasteren S.I. van (2020), Immunoproteasome inhibitor-doxorubicin conjugates target multiple myeloma cells and release doxorubicin upon low-dose photon irradiation, Journal of the American Chemical Society 142(16): 7250-7253.
- Maurits E. (7 July 2020), Targeting human proteasomes: Substrates, inhibitors and prodrugs (Dissertatie. Leiden Institute of Chemistry (LIC), Faculty of Science, Leiden University). Supervisor(s) and Co-supervisor(s): Overkleeft H.S., Kasteren S.I. van & Florea B.I.
- Maurits E. Degeling C.G. Kisselev A.F. Florea B.I. Overkleeft H.S. (2020), Structure-based design of fluorogenic substrates selective for human proteasome subunits, ChemBioChem 21(22): 3220-3224.
- Geus M.A.R. de, Groenewold G.J.M., Maurits E., Araman C. & Kasteren S.I. van (2020), Synthetic methodology towards allylic trans-cyclooctene-ethers enables modification of carbohydrates: bioorthogonal manipulation of the lac repressor, Chemical Science 11(37): 10175-10179.
- Besse A., Besse L., Kraus M., Mendez-Lopez M., Bader J., Xin B., Bruin G. de, Maurits E., Overkleeft H.S. & Driessen C. (2019), Proteasome inhibition in multiple myeloma: head-to-head comparison of currently available proteasome inhibitors, Cell chemical biology 26(3): 340-351.
- Xin B.T., Huber E.M., Bruin G. de, Heinemeyer W., Maurits E., Espinal C., Du Y., Janssens M., Weyburne E.S., Kisselev A.F., Florea B.I., Driessen C., Marel G.A., Groll M. & Overkleeft H.S. (2019), Structure-Based Design of Inhibitors Selective for Human Proteasome β2c or β2i Subunits, Journal of Medicinal Chemistry 62(3): 1626-1642.
- Gracht A.M.F. van der, Geus M.A.R. de, Camps M.G.M., Ruckwardt T.J., Sarris A.J.C., Bremmers J., Maurits E., Pawlak J.B., Posthoorn M.M., Bonger K.M., Filippov D.V., Overkleeft H.S., Robillard M.S., Ossendorp F. & Kasteren S.I. van (2018), Chemical control over T-cell activation in vivo using deprotection of trans-cyclooctene-modified epitopes, ACS Chemical Biology 13(6): 1569-1576.
- Basler M., Maurits E., Bruin G. de, Koerner J., Overkleeft H.S. & Groettrup M. (2018), Amelioration of autoimmunity with an inhibitor selectively targeting all active centres of the immunoproteasome, British Journal of Pharmacology 175(1): 38-52.
- Basler M., Lindstrom M.M., LaStant J.J., Bradshaw J.M., Owens T.D., Schmidt C., Maurits E., Tsu C., Overkleeft H.S., Kirk C.J., Langrish C.L. & Groettrup M. (2018), Co-inhibition of immunoproteasome subunits LMP2 and LMP7 is required to block autoimmunity, EMBO Reports 19(12): e46512.
- Sarris A.J.C., Hansen T., Geus M.A.R. de, Maurits E., Doelman W., Overkleeft H.S., Codée J.D.C., Filippov D.V. & Kasteren S.I. van (2018), Fast and pH-Independent Elimination of trans-Cyclooctene by Using Aminoethyl-Functionalized Tetrazines, Chemistry: a European Journal 24(68): 18075-18081.